Merrimack Pharmaceuticals was a leading public biopharmaceutical company that discovered, developed, and commercialized medicines for the treatment of cancer. Most significantly, their discovery of Onivyde, is used to improve the survival rate and progression of pancreatic cancer.
Gennari Aronson has represented Merrimack as corporate and securities counsel since 2020. In 2024, Ipsen Pharmaceuticals purchased all rights to Onivyde for $225 million and Merrimack issued a liquidating dividend to stockholders. Gennari Aronson worked with the company to develop a plan of liquidation to provide long-term capital gains tax treatment while also setting up the structure for future dividend payments for any additional transactions.
CLIENT STORY
Merrimack Pharmaceuticals
"Gennari Aronson helped to steer us through many complex issues facing public companies and assisted us in developing plans for our liquidation. We appreciated their partnership each step of the way."
Gary Crocker, CEO